- Home
- RLAY vs NRK Comparison
RLAY vs NRK Comparison
Compare RLAY & NRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- NRK
- Stock Information
- Founded
- RLAY 2015
- NRK 2002
- Country
- RLAY United States
- NRK United States
- Employees
- RLAY N/A
- NRK N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- NRK Trusts Except Educational Religious and Charitable
- Sector
- RLAY Health Care
- NRK Finance
- Exchange
- RLAY Nasdaq
- NRK Nasdaq
- Market Cap
- RLAY 803.4M
- NRK 884.6M
- IPO Year
- RLAY 2020
- NRK N/A
- Fundamental
- Price
- RLAY $6.22
- NRK $10.17
- Analyst Decision
- RLAY Strong Buy
- NRK
- Analyst Count
- RLAY 8
- NRK 0
- Target Price
- RLAY $17.25
- NRK N/A
- AVG Volume (30 Days)
- RLAY 1.7M
- NRK 187.3K
- Earning Date
- RLAY 11-05-2025
- NRK 01-01-0001
- Dividend Yield
- RLAY N/A
- NRK 4.10%
- EPS Growth
- RLAY N/A
- NRK N/A
- EPS
- RLAY N/A
- NRK N/A
- Revenue
- RLAY $8,355,000.00
- NRK N/A
- Revenue This Year
- RLAY $27.33
- NRK N/A
- Revenue Next Year
- RLAY $7.40
- NRK N/A
- P/E Ratio
- RLAY N/A
- NRK N/A
- Revenue Growth
- RLAY N/A
- NRK N/A
- 52 Week Low
- RLAY $1.78
- NRK $8.95
- 52 Week High
- RLAY $7.07
- NRK $11.09
- Technical
- Relative Strength Index (RSI)
- RLAY 71.34
- NRK 67.05
- Support Level
- RLAY $5.47
- NRK $10.10
- Resistance Level
- RLAY $7.00
- NRK $10.18
- Average True Range (ATR)
- RLAY 0.37
- NRK 0.07
- MACD
- RLAY 0.11
- NRK -0.02
- Stochastic Oscillator
- RLAY 70.90
- NRK 58.62
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About NRK Nuveen New York AMT-Free Quality Municipal Income Fund
Nuveen New York AMT-Free Quality Municipal Income Fund is a closed-end investment company. Its investment objective is to provide current income exempt from regular federal, New York State, and New York City income taxes and from the federal alternative minimum tax applies to individuals and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.